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Abstract
Background: Over the past fifteen years, we have demonstrated that cortisol and dehydroepiandrosterone (DHEA)
have opposite effects on the regulation of protein kinase C (PKC) activity in the context of the immune system. The
anti-glucocorticoid effect of DHEA is also related to the regulation of splicing of the glucocorticoid receptor (GR),
promoting the expression of GRβ isoform, which acts as a negative dominant form on GRα activity. Moreover, it is
very well known that DHEA can be metabolized to androgens like testosterone, dihydrotestosterone (DHT), and its
metabolites 3α-diol and 3β-diol, which exert their function through the binding of the androgen receptor (AR).
Based on this knowledge, and on early observation that castrated animals show results similar to those observed
in old animals, the purpose of this study is to investigate the role of androgens and the androgen receptor (AR) in
DHEA-induced expression of the PKC signaling molecule RACK1 (Receptor for Activated C Kinase 1) and cytokine
production in monocytes.
Results: Here we demonstrated the ability of the anti-androgen molecule, flutamide, to counteract the stimulatory
effects of DHEA on RACK1 and GRβ expression, and cytokine production. In both THP-1 cells and human peripheral
blood mononuclear cells (PBMC), flutamide blocked the effects of DHEA, suggesting a role of the AR in these
effects. As DHEA is not considered a direct AR agonist, we investigated the metabolism of DHEA in THP-1 cells.
We evaluated the ability of testosterone, DHT, and androstenedione to induce RACK1 expression and cytokine
production. In analogy to DHEA, an increase in RACK1 expression and in LPS-induced IL–8 and TNF–α production
was observed after treatment with these selected androgens. Finally, the silencing of AR with siRNA completely
prevented DHEA-induced RACK1 mRNA expression, supporting the idea that AR is involved in DHEA effects.
Conclusions: We demonstrated that the conversion of DHEA to active androgens, which act via AR, is a key
mechanism in the effect of DHEA on RACK1 expression and monocyte activation. This data supports the existence
of a complex hormonal balance in the control of immune modulation, which can be further studied in the context
of immunosenescence and endocrinosenescence.
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Background
In early studies aimed to characterize the molecular
mechanisms underlying immunosenescence, we identi-
fied a defective protein kinase C (PKC) activation cen-
tral to the function of immune cells. In particular, we
demonstrated that the failing element in PKC activation
was the reduced expression of its scaffold protein
Receptor for Activated C Kinase 1 (RACK1), which
underlies the functional impairment of immune system
associated with aging [1–5]. RACK1 is a 36–kDa pro-
tein that contains seven WD-domain motifs and is re-
lated to G protein β subunits [6, 7]. RACK1 is a highly
conserved intracellular adaptor protein, which was ori-
ginally identified as the anchoring protein for activated
PKC [8, 9]. In the past 20 years, the number of binding
partners and validated cellular functions for RACK1
has increased. It is believed to act as signal integrator,
which interconnects distinct signaling pathways to control
many essential cellular processes, including protein trans-
lation, developmental processes, multiple hormonal re-
sponses, pathogen infection resistance, environmental
stress responses, and miRNA production. These multiple
functional roles are fitting, considering the scaffolding
nature of RACK1 protein [10–14].
Relative to PKC, RACK1 is able to interact preferen-
tially with PKCβII [8] and PKCε [9]. RACK1 stabilizes
their active conformation and promotes their transloca-
tion to specific substrates in order to activate defined
pathways [6, 7]. Using antisense oligonucleotides to de-
crease RACK1 expression, or using a PKCβ pseudosub-
strate to selectively inhibit PKCβ activation, a significant
reduction in LPS-induced monocytes/macrophages activa-
tion was observed, indicating the involvement of RACK1
and PKCβ in the signal transduction pathways triggered
by LPS [1, 15].
The role of hormones in the control of RACK1 ex-
pression was suggested by a series of experimental evi-
dence. While in old rats there is evidence that RACK1
expression and LPS-stimulated production of tumor
necrosis factor-α (TNF α) is reduced in alveolar macro-
phages, we demonstrated that castration of young male
rats produced effects on alveolar macrophages similar
to those of aging. Conversely, the supplementation of
dehydroepiandrosterone (DHEA) to old rats restored the
age-decreased level of RACK1, LPS-stimulated production
of TNF α in alveolar macrophages, and mitogen-induced
splenocyte proliferation, suggesting that immunosenes-
cence is partially under hormonal control and can be re-
stored by appropriate replacement therapy [2].
Similarly, we also observed a direct correlation be-
tween circulating DHEA and RACK1 expression in
human peripheral blood leukocytes. In vitro treatment
with physiological concentrations of DHEA resulted in in-
creased RACK1 expression in leukocytes and lymphocyte
proliferation, confirming the role of this hormone in
the modulation of RACK1 expression and immune
functions [3].
DHEA is the most abundantly secreted adrenal ster-
oid in humans. It is known to increase throughout
childhood and puberty, and then to decrease with old
age. The average serum DHEA concentration in men
aged 25–34 is 15.9 + 6.1 nM but falls to 5.4 + 1.7 nM in
those aged 75–85 [16]. Reduced secretion of DHEA dur-
ing aging has been related to a series of age-associated
conditions, including atherosclerosis and cardiovascular
disease, breast cancer, obesity, loss of muscle mass, and
diabetes; there is a view that supplementation with DHEA
may have a number of significant clinical uses [17].
It is well documented that DHEA affects multiple cel-
lular functions of the endocrine, immune, and nervous
systems. However, despite intense effort by scientists to
elucidate the multifunction of DHEA, its mechanism
of action is still elusive. Most of its physiological ac-
tions have been attributed to its conversion to either
androgens or estrogens. Depending on the tissue, DHEA
can be indeed metabolized to 4-androstenedione, 5α-
androstenedione, testosterone, estrogen, and other bio-
logically active steroids [18, 19].
More recently, we demonstrated in THP-1 cells that
DHEA can antagonize physiological functions of en-
dogenous glucocorticoid [20] inducing a dose-related
up-regulation of GRβ, through a modulation in the
expression of the splicing-related protein SRp30c.
Moreover, GRβ knockdown prevented DHEA-induced
RACK1 expression and modulation of cytokine release
[21]. This data indicated the ability of GRβ to act as a
dominant-negative inhibitor of GRα function, which
could underlie the anti-glucocorticoid effect of DHEA
on RACK1 protein expression.
Glucocorticoid, progestin, and androgen hormones
function via their specific receptors, which recognize a
common DNA binding site: the glucocorticoid response
element (GRE) or hormone response element (HRE).
HRE can function as a response element for all steroid
classes except for estrogens, allowing extensive cross-
talk between receptors and shared target genes [22, 23].
To shed light on the mechanisms underlying DHEA-
induced RACK1 expression and cytokine production in
monocytes, we investigated the role of androgens and
androgen receptor on DHEA effects. Collectively, our
findings demonstrate that, similarly to DHEA, other an-
drogens exerted stimulatory effects on immune cells,
and AR silencing completely prevented DHEA-induced
RACK1, supporting the notion that DHEA conversion
to androgens and AR are central to the biological ef-
fects of DHEA in monocytes. This data further contrib-
utes to our understanding of the mechanism of action
of DHEA.
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Methods
Chemicals
Four-Androstene-3, 17-dione (androstenedione), DHEA,
DHT, 3α-DIOL, 3β-DIOL, flutamide (Flut), testosterone
were obtained from Sigma Aldrich (St Louis, MO, USA).
Steroids were dissolved in dimethyl sulfoxide (DMSO) at
50 mM and further diluted (the final concentration of
DMSO in culture medium was 0.2 %). Lipopolysaccharide
from Escherichia coli serotype 0127:B8 (LPS) was from
Sigma Aldrich. All cell culture reagents and supplements
were from Sigma. Antibodies against RACK1 and AR were
from BD Biosciences (Franklin Lakes, NJ, USA), GRβ
from Abcam (Cambridge, UK), and anti-human β-actin
from Sigma Aldrich. AR siRNA and scrambled controls
were from Cell Signaling Technology (Danvers, MA,
USA). Electrophoresis reagents were from Bio-Rad
(Hercules, CA, USA). All reagents were purchased at the
highest purity available.
Cells
THP-1 cells, obtained from Istituto Zooprofilattico di
Brescia (Italy), were diluted to 106 cells/mL in RPMI
1640 without phenol red containing 2 mM L-glutamine,
0.1 mg/mL streptomycin, 100 IU/mL penicillin, gentamy-
cin 10 μg/ml, 50 μM 2–mercaptoethanol, supplemented
with 5 % heated-inactivated dialyzed fetal calf serum
(culture media) and cultured in suspension at 37 °C in 5 %
CO2 incubator. Cells were treated as reported in the le-
gend to figures.
Human volunteers and ethical statement
Peripheral blood mononuclear cells (PBMCs) were iso-
lated by Ficoll gradient centrifugation from fresh blood
of human volunteers. Five healthy females (23–52 year-
old) were selected according to the guidelines of the
Italian Health authorities, and to the Declaration of
Helsinki principles, within a protocol approved by the Eth-
ics Committee of the University of Pavia (NCT01345110),
and signed an informed consent. Following centrifugation
at 900 g at 25 °C for 30 min with no brake, the PBMCs
layer was removed and washed twice in Hanks’ balanced
salt solution (HBSS). PBMCs were resuspended at 106/ml
in culture media and treated as reported in the legend to
figures.
Cell viability
Cytotoxicity was assessed by leakage of lactate dehydro-
genase (LDH). LDH activity was determined in cell-
free supernatants using a commercially available kit
(Takara Bio Inc., Japan). Results are expressed as optical
density (OD).
Real time RT-PCR
Total RNA was isolated at different times of treatment
using a commercially available kit (TriReagent from
Sigma) following the supplier’s instructions. For the syn-
thesis of cDNA, 2.0 μg of total RNA was retro-transcribed
using the High-Capacity cDNA Archive Kit from Applied
Biosystems (Foster City, CA, USA) following the supplier’s
instructions. RACK1 gene expression was evaluated by
real-time reverse transcription-polymerase chain reaction
(Real-time PCR). For PCR-analysis, Taq-ManTM-PCR
technology was used. PCRs were performed in duplicate
and according to the standard protocol suggested by the
manufacturer. For each PCR reaction, 10 ng of total RNA
were used. The 18S ribosomal RNA transcription was
used as endogenous reference, and the quantification of
the transcripts was performed by the 2-ΔΔCT method [24].
Western blot analysis
The presence of RACK1 and AR in cell homogenates
was assessed by Western blot analysis. Briefly, cells
(3x106) were treated as described in the legends. At the
end of treatments, cells were collected, washed once with
PBS, centrifuged and lysed in 100 μl of homogenization
buffer (50 mM TRIS, 150 mM NaCl, 5 mM EDTA pH 7.5,
0.5 % Triton X-100, 50 μM PMSF, 2 μg/mL aprotinin,
1 μg/mL pepstatin and 1 μg/mL leupeptin) and denatured
for 10 min at 100 °C. The protein content of the cell lysate
was measured using a commercial kit (Bio-Rad). 5 μg (for
RACK1) or 10 μg (for GRβ and AR) of extracted proteins
were electrophoresed in a 12 % SDS-polyacrylamide gel
under reducing conditions. The proteins were then trans-
ferred to PVDF membrane (Amersham, Little Chalfont,
UK). The proteins were visualized using primary anti-
bodies for RACK1 (1:1000), GRβ (1:1000), AR (1:1000)
and β–actin (1:5000) and developed using enhanced
chemiluminescence (Pierce, Thermo Scientific, Rockford,
IL, USA). The image of the blot was acquired and ana-
lyzed with the Molecular Imager Gel Doc XR (BioRad).
Cytokine production
Cytokine production was assessed in cell free supernatants
by specific sandwich ELISAs, commercially available
(R&D System, Minneapolis, MN, USA). Cell-free superna-
tants obtained by centrifugation at 1200 rpm for 5 min
were stored at −20 °C until measurement. Limits of detec-
tion were 15 pg/ml. Results are expressed in pg/ml.
Quantitative analysis of steroids by LC-MS/MS
Intracellular testosterone and its metabolites DHT, 3α–
DIOL and 3β–DIOL were assessed by LC-MS/MS as
previously described [25]. Cells (1 × 107) were treated
with DHEA 10 nM or DMSO as vehicle control for 1 h,
washed twice with PBS and lysed. Samples, added with
13C internal standards, were extracted and purified with
Corsini et al. Immunity & Ageing  (2016) 13:20 Page 3 of 10
1 ml of MeOH/acetic acid (99:1, v/v). The organic phases
were passed through an SPE cartridge, steroids fraction
concentrated and transferred into auto-sampler vials be-
fore LC–MS/MS analysis. Quantitative analysis was per-
formed on the basis of calibration curves prepared and
analyzed as described above for samples. Positive atmos-
pheric pressure chemical ionization (APCI) experiments
were performed using a linear ion trap-mass spectrometer
(LTQ, ThermoElectron Co., San Jose, CA, USA) and the
LC mobile phases were (A) H2O/0.1 % formic acid and
(B) methanol (MeOH)/0.1 % formic acid. The gradient
(flow rate 0.5 ml/min) was described previously [25].
Small interference RNA (siRNA) for AR
To evaluate the role of AR in DHEA-induced RACK1
expression, silencing experiments were conducted. The
effect of inducing RNA interference on AR was assessed
using commercially available reagents (SignalSilence™
siRNA from Cell Signaling Technology) following the
manufacturer’s instructions. As control, siRNA (scr), an
siRNA sequence that will not cause the specific degrad-
ation of any cellular messages was used. Forty-eight
hours after siRNA transfection, Western blot analysis
using AR antibody was performed to confirm silencing
in whole cell lysates. Cells were then adjusted to 106/ml
and treated with DHEA (10 nM) or DMSO as vehicle
control for 16 h to assess RACK1 mRNA expression and
24 h to assess RACK1 protein expression.
Statistical analysis
All experiments were performed at least three times,
with representative results shown. Data are expressed as
mean ± standard deviation (SD). Statistical analysis was
performed using GraphPad InStat version 3.0a for
Macintosh (GraphPad Software, San Diego, CA, USA).
Differences were considered significant at p ≤ 0.05.
Results
The anti-androgen flutamide prevents the stimulatory
effects of DHEA on RACK1 expression and cytokine
production
The aim of this study was to investigate the role of
androgens and AR in the immunostimulatory effects of
DHEA. To address this question, we first investigated
the ability of the anti-androgen flutamide to modulate
the stimulatory effects of DHEA in both the human pro-
myelocytic THP-1 cell line, and in human peripheral
blood mononuclear cells (PBMCs). THP-1 is a human
leukemia monocytic cell line derived from the peripheral
blood of a 1-year-old human male with acute monocytic
leukemia. This cell line has been extensively used to
study monocyte/macrophage functions, mechanisms,
and signaling pathways [26]. PBMCs were obtained from
five adult healthy females (28-year-old) and were used to
support the relevance of data obtained in THP-1 cells
and to exclude possible gender effects. THP-1 cells
and PBMCs were treated for 1 h with flutamide
(50 μM), then a physiologically relevant concentration
of DHEA (10 nM) or DMSO as vehicle control was
added. After 16 h of treatment, Real Time-PCR was
used to assess RACK1 mRNA expression. In both
experimental models, flutamide completely prevented
DHEA-induced RACK1 mRNA expression (Fig. 1a and b),
suggesting the role of AR in the effect of DHEA on
RACK1 expression.
The rest of the data presented was conducted using
THP-1 cells. Next, the effect of flutamide on DHEA-
induced RACK1 protein expression and cytokine pro-
duction was investigated. Cells were treated with DHEA
for 24 h as optimal time for RACK1 protein expression
[27]. After DHEA treatment, LPS (10 ng/ml) was added
for 3 and 24 h to assess TNF-α and IL-8 release, respect-
ively. Flutamide not only prevented DHEA-induced
RACK1 mRNA expression, but also RACK1 protein
expression as assessed by Western blot analysis (Fig. 1c),
and cytokine production as assessed by LPS (10 ng/ml)-
induced TNF-α and IL-8 release (Fig. 1e and f). Similar
inhibitory effects on LPS-induced cytokine production
were observed in human PBMC treated with DHEA in
the presence of flutamide (data not shown). The release
of TNF-α and IL-8 in DMSO treated cells was below the
detection limit of the ELISA (data not shown). The in-
hibitory effect of flutamide was not due to cytotoxicity,
as assessed by identical LDH leakage in control and
treated cells: in control cells the optical density (OD)
value was 0.582 ± 0.023 vs 0.597 ± 0.017 in flutamide
treated cells.
Furthermore, considering the anti-glucocorticoid effect
of DHEA, mediated by the induction of GRβ [21], we
demonstrate here that flutamide also prevents DHEA-
induced GRβ protein expression (Fig. 1d). This data
clearly indicates that AR is central to the action of DHEA,
and confirms early data obtained in experimental animals
on the role of androgens in the maintenance of RACK1
expression and immune function [2].
DHEA is metabolized to androgens in THP-1 cells, and
other androgens have a similar effect to that of DHEA
Most of DHEA physiological actions have been attrib-
uted to its conversion to either androgens or estrogens,
therefore, we investigated the ability of THP-1 cells to
metabolize DHEA. THP-1 cells were treated for 1 h with
DHEA (10 nM) or DMSO as vehicle control. Testoster-
one, DHT, and its metabolites 3α-diol and 3β-diol were
evaluated by LC-MS/MS in cell lysates (Fig. 2a). Data
indicates the ability of THP-1 cells to rapidly convert
DHEA to androgens. This finding prompted us to inves-
tigate the ability of the androgens testosterone, DHT,
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and 4-androstenedione, the first intermediate of DHEA
in the synthesis of testosterone, to induce RACK1 ex-
pression and cytokine production. In analogy to DHEA,
an increase in RACK1 expression (both mRNA and
protein) and in LPS-induced IL-8 and TNF-α produc-
tion was observed after treatment with these androgens
(Figs. 2 and 3). The role of DHT in DHEA-induced
RACK1 expression was also corroborated by the ability
of finasteride, a 5α-reductase inhibitor, to completely
block the effect of DHEA on RACK1 mRNA expression
(Fig. 2b).
In details, THP-1 cells were treated with increasing con-
centrations of testosterone (1–100 nM). These concentra-
tions are physiologically relevant, as the ranges of plasma
levels of testosterone in female are 0.7-3 nM, and 10–50
nM in male. Testosterone was able to induce a dose-
related increase of RACK1 mRNA expression (Fig. 2c), and
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Fig. 1 The anti-androgen flutamide prevents DHEA-induced effects. a, b RACK1 mRNA expression. THP-1 cells (a) or PBMC (b) were treated with
flutamide (50 μM) or DMSO for 1 h, followed by DHEA (10 nM) or DMSO for 16 h. DMSO (0.1 % final concentration) was used as vehicle control
in all experiments. RACK1 mRNA expression was assessed by Real Time-PCR. Results are expressed as mean ± SD of three independent experiments
(a) or as dots of individual donors responses (b). *p < 0.05 vs Control cells and §p < 0.05 vs DHEA alone. c, d Representative Western blot
analyses of RACK1 (c) or GRβ (d) immunoreactivity in THP-1 cells. β-Actin immunoreactivity was used as protein loading control. Representative
Western blots are reported. Cells were treated with flutamide (Flut, 50 μM) or DMSO (Cont) for 1 h and then DHEA (10 nM) or DMSO was added for
24 h. e, f Effect on cytokine production. THP–1 cells were treated with flutamide (50 μM) for DMSO or 1 h, and then DHEA (10 nM) or DMSO was
added. After 24 h, LPS (10 ng/ml) was added for 3 h to assess TNF-α release (e) or 24 h to assess IL–8 release (f). Results are expressed as mean ± SD,
n = 3 replicates. Data is representative of three independent experiments. Statistical analysis was performed with Tukey’s multiple comparison test with
**p < 0.01 vs LPS treated cells and §§, p < 0.01 vs DHEA + LPS treated cells
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Fig. 2 DHEA is metabolized to DHT in THP–1 cells; and testosterone (similarly to DHEA) affects RACK1 expression. a DHEA metabolism. THP–1
cells (107) were treated with (10 nM) or DMSO as vehicle control for 1 h. Testosterone, DHT, and its metabolites 3α-diol and 3β-diol were assessed
by LC-MS/MS in cell lysates. Each dot represents the mean ± SD of 4 samples obtained in two independent experiments. b The 5α-reductase
inhibitor finasteride blocks DHEA-induced RACK1 expression. THP-1 cells were treated with finasteride (0.1 μM) for 1 h and then DHEA (10 nM) or
DMSO as vehicle control was added for 16 h. RACK1 mRNA expression was assessed by Real Time-PCR. Results are expressed as mean ± SD of
three independent experiments, with §p < 0.05 vs DHEA alone. c, d Testosterone induces a dose-related increase in RACK1 expression. THP-1 cells
were treated with increasing concentrations of testosterone (1–100 nM) or DMSO as vehicle control for 16 h for mRNA expression (c) or 24 h for
protein expression (d). RACK1 mRNA expression was assessed by Real Time-PCR. Results are expressed as mean ± SD of four independent experiments,
with *p < 0.05 vs Control cells. RACK1 immunoreactivity was assessed by Western blot analysis of cell lysates. β-Actin immunoreactivity was used as
protein loading control and to normalize RACK1 expression. A representative Western blot is reported together with a densitometric analysis of data
obtained from three independent experiments. Results are expressed as mean ± SD, with *p < 0.05 vs Control cells. e, f Effect of testosterone
on LPS-induced cytokine production. THP-1 cells were treated with increasing concentrations of testosterone (1–100 nM) or DMSO as vehicle
control. After 24 h, LPS (10 ng/ml) was added for 3 h to assess TNF-α release (e) or 24 h to assess IL–8 release (f). Results are expressed as
mean ± SD, n = 3 replicates. Data is representative of three independent experiments. Statistical analysis was performed with Tukey’s multiple
comparison test with §p < 0.05 and §§p < 0.01 vs LPS treated cells
Corsini et al. Immunity & Ageing  (2016) 13:20 Page 6 of 10
significant increase in the response to LPS (10 ng/ml) as
assessed by TNF-α and IL-8 release (Fig. 2e). 10 nM testos-
terone was the most effective concentration.
As shown in Fig. 3, THP-1 cells were treated with DHT
(1 and 10 nM) and 4-androstenedione (10 nM) for 16 h to
assess the effect on mRNA expression (Fig. 3a), or 24 h
for protein expression (Fig. 3b). Following 24 h of treat-
ment with DHT or 4-androstenedione, LPS (10 ng/ml)
was added for 3 and 24 h to assess TNF-α and IL-8
release, respectively (Fig. 3c and d). Both DHT and 4-
androstenedione were able to significantly increase
RACK1 mRNA and protein expression, as well as the
response to LPS. Compared to testosterone, DHT ap-
pears to be more potent: at 1 nM the increase in RACK1
expression and in LPS-induced cytokine production was
already statistically significant, whereas testosterone 1
nM was ineffective (Fig. 2). This is consistent with the
notion that DHT is more potent than testosterone.
Finally, to confirm that AR is necessary to mediate
DHEA-induced RACK1 expression, silencing experi-
ments were conducted. As shown in Fig. 4, AR silencing
completely prevented DHEA-induced RACK1 mRNA and
protein expression, supporting the notion that AR is in-
deed involved in DHEA effects. Additional confirmation
of the link between AR and the expression of RACK1
came from the observation that the silencing of AR is
associated with a reduction in RACK1 immunoreactivity,
as assessed by Western blot analysis of cell lysates follow-
ing 48 h of silencing (Fig. 4).
Discussion
DHEA has been reported to have several beneficial effects
in aging humans [17, 19, 28], and it is therefore of interest
to determine the mechanisms behind these diverse effects,
which are still incompletely understood. In addition, with

































































































































Fig. 3 DHT and androstenedione, similarly to DHEA, affect RACK1 expression. a, b Increased RACK1 expression following treatment with DHT and
androstenedione. THP-1 cells were treated with increasing concentrations of DHT (1–10 nM), androstenedione (10 nM) or DMSO as vehicle control
for 16 h for mRNA expression (a) or 24 h for protein expression (b). RACK1 mRNA expression was assessed by Real Time-PCR. Results are expressed as
mean ± SD of three independent experiments, with *p < 0.05 and **p < 0.01 vs Control cells. RACK1 immunoreactivity was assessed by Western blot
analysis of cell lysates (b). A representative Western blot of RACK1 immunoreactivity in cell lysate is shown. c, d Effect of DHT and androstenedione on
LPS-induced cytokine production. THP–1 cells were treated with increasing concentrations of DHT (1–10 nM), androstenedione (10 nM) or DMSO as
vehicle control. After 24 h, LPS (10 ng/ml) was added for 3 h to assess TNF-α release (c) or 24 h to assess IL–8 release (d). Results are expressed
as mean ± SD, n = 3 replicates. Data is representative of three independent experiments. Statistical analysis was performed with Tukey’s multiple
comparison test with §p < 0.05 and §§p < 0.01 vs LPS treated cells
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the mechanism of action of this sterol and its metabolites
is important to study. The main purpose of this study was
to shed light on the mechanism underlying the effect of
DHEA on RACK1 expression and on the activation of
innate immune cell, as well as to reconcile data we have
accumulated over the last fifteen years [2, 21]. In the
present manuscript, our results indicate that the activation
of AR is central to the action of DHEA on RACK1 expres-
sion and cytokine release. In THP-1 cells, we found that
DHEA is rapidly converted to DHT and downstream me-
tabolites. We demonstrated that the effect of DHEA and
its metabolites on RACK1 expression could be completely
prevented by using flutamide as an AR antagonist, block-
ing the expression of the receptor by siRNA, or using fi-
nasteride to block DHT synthesis, strongly suggesting a
pivotal role of androgens and AR in RACK1 modulation.
Overall, these findings contribute to our understanding of
the physiological role of hormones in monocyte functions,
and support the use of DHEA to manipulate monocyte ac-
tivation and to counteract immunosenescence. However,
the need for large, long-term placebo controlled clinical
trials to demonstrate safety and efficacy of DHEA is still
an open question [17].
We have previously demonstrated that cortisol and
DHEA have opposite effects on the regulation of PKC
activity involved in immune processes such as cytokine
release and lymphocyte proliferation [2, 27]. Physiological
concentrations of cortisol exert an inhibitory effect on
RACK1 expression through the presence of a glucocortic-
oid receptor (GR)-responsive sequence on the promoter
region of the human guanine nucleotide-binding protein
β-2-like 1 (GNB2L1) gene, which codes for RACK1 pro-
tein [29]. Conversely, treatment with DHEA could restore
the levels of RACK1 protein both in vivo and in vitro [2].
In the context of the immune system, we demonstrated
that the anti-glucocorticoid effect of DHEA on RACK1
expression, and the related PKC signaling, may be due to
the influence of DHEA on alternative splicing of the
mRNA coding for the human GR in favor of the ex-
pression of the β isoform [21]. In the current manu-
script, we show that by blocking AR using flutamide,
DHEA-induced GRβ protein expression could be com-
pletely prevented, positioning AR at the center of the ac-
tion of DHEA. In both human PBMC and THP-1 cells,
flutamide prevented DHEA-induced RACK1 mRNA ex-
pression and LPS-induced cytokine production. Similarly,
blocking the expression of the receptor by the use of
siRNA, the actions of DHEA on the same mechanisms
was impaired.
DHEA mediates its action via several signaling path-
ways involving specific membrane receptors. These
pathways and receptors include the G-coupled protein
receptors demonstrated in bovine aortic endothelial
cells and human umbilical vein endothelial cells, the
σ1-receptor in neurons, and via transformation into an-
drogen and estrogen derivatives acting through their
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Fig. 4 AR silencing prevents DHEA-induced RACK1 expression. THP-1
cells were transfected with transfection reagent alone (no oligo) or
with siRNA (60 nmol) targeted to AR (siAR) or with control siRNA (scr).
After 48 h, extracts were prepared for Western blot analysis of AR,
RACK1 and β-actin (loading control) immunoreactivity to estimate AR
knockdown efficiency (inset). After silencing, cells were incubated with
DHEA (10 nM) or DMSO as vehicle control for 16 h to assess mRNA
expression (a) and 24 h to assess protein expression (b). Results are
expressed as mean ± SD of three independent experiments, with
*p < 0.05 and **p < 0.01 vs control cells, and §p < 0.05 vs no oligo
or siSCR treated cells
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specific DHEA responsive nuclear receptor has been iden-
tified to date; and it is believed that the majority of physio-
logical actions of DHEA should be attributed, depending
on the tissue, to its conversion to either androgens or
estrogens [19]. In THP-1 cells, we found that DHEA was
converted to DHT, with its downstream metabolites 3α-
diol and 3β-diol already appearing after 1 h of exposure.
To support the role of androgens in DHEA effects, we
found that by blocking 5α-reductase with finasteride,
which prevents the conversion of testosterone to DHT as
well as the conversion of 4-androstene-3,17-dione to 5α-
androstanedione (which is then metabolized by 17β-
hydroxysteroid oxidoreductase to DHT), DHEA-induced
RACK1 expression can be prevented, implicating DHT as
an effector androgen. The positive modulation of RACK1
expression induced by the androgenic effect of DHEA
results in an increased response to LPS, as assessed by
cytokine production. Compared to testosterone, DHT
appears to be a more potent stimulus. At 1 nM DHT was
already active, whereas testosterone at the same concentra-
tion was ineffective; this is in accordance with the higher
stability of the DHT-AR complex [30].
Cadwallader et al. [31] have investigated hAR and hGR
nuclear translocation in transiently transfected COS
cells. Specific ligands induce rapid and robust nuclear
translocation, without cross reactivity. For testosterone
there was a slightly higher rate of transport calculated
for the 50 nM dose than the 100 nM, which may explain
the slightly lower activity of testosterone 100 nM that
we observed compared to 10 nM (Fig. 2). This could be
of physiological significance, since 10 nM is close to the
physiological concentrations of androgens (0.7-3 nM in
females and 10–50 nM in males). The loss of the immu-
nostimulatory effect of DHEA by blocking or silencing the
AR is consistent with the observation that AR ablation in
myeloid cells tends to establish an immunosuppressive
environment [32, 33].
Conclusions
Overall, these data, together with the ability of physiolo-
gically relevant concentrations of testosterone and DHT
to induce RACK1 expression, supports the notion that
the metabolic transformation of DHEA to androgens
and their binding to AR are required for DHEA-induced
RACK1 expression and cell activation. Additional studies
are required to fully understand the mechanism of AR
action following DHEA treatment, especially the assess-
ment of specific targets and/or coregulatory proteins re-
cruited, which may also contribute to the effect of AR
via interference and modulation of GR splicing isoform
production, and in turn, their effects on the promoter
region of GNB2L1 gene coding for RACK1 protein.
Hormones have an important role in homeostasis and
function of the immune system. Sex hormones appear to
have distinctive and exclusive roles in the development of
the immune system and in shaping the immune responses
[34]. It is intriguing to note that pharmacological concen-
trations of androgens have been reported to reduce im-
mune cell activation (reviewed in ref [35]).
We identified DHEA conversion to androgens and bind-
ing to AR as necessary steps in DHEA-induced cell activa-
tion, and considering the opposite effect of cortisol, the
data supports the existence of a complex hormonal bal-
ance between cortisol and androgens, which orchestrates
RACK1 expression and monocyte activation, leading the
way to novel therapeutic targets for immune modulation.
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